Sensato Investors LLC bought a new position in Novartis AG (NYSE:NVS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 36,300 shares of the company’s stock, valued at approximately $3,048,000.
Several other institutional investors have also bought and sold shares of NVS. Stevens Capital Management LP bought a new stake in shares of Novartis in the 3rd quarter worth $443,000. Bessemer Group Inc. grew its holdings in shares of Novartis by 21.5% in the third quarter. Bessemer Group Inc. now owns 15,168 shares of the company’s stock worth $1,303,000 after acquiring an additional 2,679 shares during the period. Jarislowsky Fraser Ltd grew its holdings in shares of Novartis by 15.2% in the third quarter. Jarislowsky Fraser Ltd now owns 207,504 shares of the company’s stock worth $17,814,000 after acquiring an additional 27,455 shares during the period. CIBC Asset Management Inc bought a new stake in shares of Novartis in the third quarter worth $5,106,000. Finally, Toronto Dominion Bank grew its holdings in shares of Novartis by 24.1% in the third quarter. Toronto Dominion Bank now owns 12,725 shares of the company’s stock worth $1,095,000 after acquiring an additional 2,469 shares during the period. 10.80% of the stock is owned by institutional investors and hedge funds.
Shares of Novartis AG (NVS) opened at $82.26 on Wednesday. Novartis AG has a fifty-two week low of $72.67 and a fifty-two week high of $94.19. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $192,140.30, a PE ratio of 25.31, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78.
Several brokerages recently commented on NVS. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Four analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $87.51.
COPYRIGHT VIOLATION WARNING: “Sensato Investors LLC Buys New Holdings in Novartis AG (NVS)” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/03/14/sensato-investors-llc-buys-new-holdings-in-novartis-ag-nvs.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.